Drug ID:Drug187
Drug Name:Tilpisertib Fosmecarbil
CID:155407072
DrugBank ID:DB18797
Modality:Small Molecule
Groups:NULL
US Approved:NO
Other Approved:NO
Identifier: NCT06029972
Molecular Formula:C35H36ClN8O7P
Molecular Weight:747.1 g/mol
Isomeric SMILES:CC(C)(C)CNC1=C2C=C(C=C(C2=NC=C1C#N)Cl)N([C@@H](C3=CC=CC4=C3C=CN(C4=O)C)C5=CN(N=N5)C67CC(C6)C7)C(=O)OCOP(=O)(O)O
Synonyms:Tilpisertib fosmecarbil; 2567459-64-5; Tilpisertib fosmecarbil [INN]; H1W0G02O9T; UNII-H1W0G02O9T; (Phosphonooxy)methyl N-((S)-(1-(bicyclo(1.1.1)pentan-1-yl)-1H-1,2,3-triazol-4-yl)(2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)-N-(8-chloro-3-cyano-4-((2,2-dimethylpropyl)amino)quinolin-6-yl)carbamate; phosphonooxymethyl N-[(S)-[1-(1-bicyclo[1.1.1]pentanyl)triazol-4-yl]-(2-methyl-1-oxoisoquinolin-5-yl)methyl]-N-[8-chloro-3-cyano-4-(2,2-dimethylpropylamino)quinolin-6-yl]carbamate; (phosphonooxy)methyl N-[(S)-[1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl](2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl]-N-{8-chloro-3-cyano-4-[(2,2-dimethylpropyl)amino]quinolin-6-yl]carbamate; SCHEMBL22797007; GTPL12081
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis PHASE2 RECRUITING Gilead Sciences Ulcerative Colitis DRUG: Tilpisertib Fosmecarbil|DRUG: Placebo Details
NCT04624230 Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis PHASE3 RECRUITING Pfizer Ulcerative Colitis DRUG: tofacitinib Details
NCT06651281 Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) PHASE3 RECRUITING Merck Sharp & Dohme LLC Crohn Disease|Colitis, Ulcerative DRUG: Tulisokibart|DRUG: Placebo to tulisokibart Details
NCT04985968 The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis PHASE3 TERMINATED InDex Pharmaceuticals Ulcerative Colitis DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… Details
NCT06681181 A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants PHASE1 RECRUITING GlaxoSmithKline Colitis, Ulcerative DRUG: GSK4528287|DRUG: Placebo Details
NCT06353828 Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients PHASE2 ACTIVE_NOT_RECRUITING CannaMore Biotechs Ulcerative Colitis DRUG: CBD, synthetic form|DRUG: Placebo Details
NCT06321887 EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD PHASE3 RECRUITING Liverpool University Hospitals NHS Foundation Trust Inflammatory Bowel Disease|Iron Deficiency Anemia DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… Details
NCT01011322 A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis PHASE2 UNKNOWN Lipid Therapeutics GmbH Ulcerative Colitis|Large Intestine|Diarrhea|Abdom… DRUG: LT-02|DRUG: placebo Details
NCT02610569 Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis None COMPLETED Dr. Arnaud Bourreille Ulcerative Colitis DEVICE: standard endoscopy|DEVICE: PillCamCOLON (… Details
NCT06109441 Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics PHASE2 RECRUITING AltruBio Inc. Ulcerative Colitis BIOLOGICAL: ALTB-268 Details
NCT06420492 Study of Novel Therapeutics for Acute Remedy of Colitis PHASE2 NOT_YET_RECRUITING Brigham and Women's Hospital Ulcerative Colitis|Ulcerative Colitis Chronic Mod… DRUG: BRS201 Details
NCT02039505 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis PHASE3 COMPLETED Takeda Ulcerative Colitis DRUG: Vedolizumab|DRUG: Vedolizumab placebo Details
NCT02392221 Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011). None COMPLETED Centre Hospitalier Universitaire, Amiens Pediatric Inflammatory Bowel Disease None Details
NCT05907330 Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis PHASE2 NOT_YET_RECRUITING Curacle Co., Ltd. Ulcerative Colitis DRUG: CU104|DRUG: Placebo Details
NCT01100112 (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets PHASE3 COMPLETED Bausch Health Americas, Inc. Colitis, Ulcerative DRUG: Budesonide Details
NCT06636656 A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis PHASE2 RECRUITING Boehringer Ingelheim Ulcerative Colitis DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… Details
NCT04996797 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) PHASE2 ACTIVE_NOT_RECRUITING Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Ulcerative Colitis DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… Details
NCT03832400 Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC) PHASE1 COMPLETED NuBiyota Ulcerative Colitis BIOLOGICAL: MET-2|DRUG: Placebo oral capsule Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT01959282 A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis PHASE2 COMPLETED Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations